PYPD PolyPid Ltd. Full Business Value

Market fluctuations in PolyPid Ltd. (PYPD) shares on GURU.Markets reflect an enterprise value of 102.25, supported by patent protection for slow-release antibiotic delivery systems and entry into profitable distribution channels. The business relies on the PLEX method for targeted wound treatment, minimizing the risk of complications. This segment possesses exceptional crisis resilience, as surgery remains in demand regardless of economic conditions.

PYPD (PolyPid Ltd) Total Company Value history from 11/23/2025 to 10/27/2026

PolyPid (PYPD) - metric breakdowns and financial figures

- price and consensus price forecast:

Market Price PolyPid Ltd|PYPD - Price Target Chart

- market capitalization data:

Market Valuation PolyPid|PYPD - Enterprise Value

- book capitalization data:

Equity per Share PolyPid|PYPD - Company Book Value|Market Capitalization to Net Assets polypid.com|PYPD - Company Total Assets

- debt and liquidity data:

All Debt to Shareholders' Equity Ratio PolyPid Ltd.|PYPD - Long-Term Debt to Capital|Short-Term Debt to Capital PolyPid Ltd|PYPD - Company Debts|Debt to Net Assets Ratio PolyPid

Comprehensive company analysis:PolyPid Ltd. (PYPD)

Investments in the development of drug delivery systems require an assessment of all PolyPid Ltd. resources. This indicator aggregates market capitalization and net debt, excluding cash and cash equivalents. By analyzing the enterprise value, an investor sees the actual price for a full buyout of the business. This allows for an evaluation of the capital intensity of the chemists' and engineers' research. The final issuer profile reveals the true scale of the company without market distortions.

Competitor analysis for PolyPid Ltd.

Summit Therapeutics plc - Total Enterprise Value|Total Company Value Moderna Corp|PCVX - Full Business Value|Enterprise Value Tarsus Pharmaceuticals|CRMD (cormedix.com) - Business Value|Total Company Value Seres Therapeutics, Inc. MCRB|Full Business Value Spero Therapeutics Inc|SCYNEXIS, Inc. (SCYX) - Enterprise Value|Value Adjusted for Debt and Cash an2therapeutics.com (ANTX)|Enterprise Value LSB (LakeShore Biopharma Co.)|Iterum Therapeutics PLC - Enterprise Value|Total Company Value BiomX Ltd (PHGE)|SNGX: Value Adjusted for Debt and Cash|SXTP (60degreespharma.com) - Total Company Value|oragenics.com (OGEN) - Real Price to Acquire Entire Company|ONCO (Onconetix, Inc.) - Enterprise Value|Enterprise Value opgen.com (OPGN)